The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: A randomized phase II study.
Completed
- Conditions
- Stem cell mobilization in healthy HLA- matched adult sibling donors with plerixafor. Patients diagnosed with Leukemia/myelodysplasia eligible for allogeneic stem cell transplantation
- Registration Number
- NL-OMON20418
- Lead Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedP.O. box 52013008 AE RotterdamTel: +31 10 7041560Fax: +31 10 7041028e-mail: hdc@erasmusmc.nl
- Brief Summary
Transfusion-59-316_Jan2019
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Donors:
1. HLA identical sibling donor;
Exclusion Criteria
Donors:
1. Monozygotic twin;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the feasibility of plerixafor 320 μg/kg subcutaneously and of plerixafor 320 μg/kg intravenously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight.<br /><br>Feasibilty is defined as a minimum of 2.0x106/kg CD34+ cells in one or two phereses in at least 90% of the donors.
- Secondary Outcome Measures
Name Time Method